"Preclinical models" trang 1 - tải miễn phí từ tailieunhanh
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
13    80    1
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models

Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
10    52    1
Isolation and characterization of two canine melanoma cell lines: New models for comparative oncology

Isolation and characterization of two canine melanoma cell lines: New models for comparative oncology
16    71    1
Advancing preclinical cancer models to assess clinically relevant outcomes

Advancing preclinical cancer models to assess clinically relevant outcomes
3    4    1
SITUATION MODELS AND LEVELS OF COHERENCE

SITUATION MODELS AND LEVELS OF COHERENCE
252    80    0
Báo cáo sinh học:

Báo cáo sinh học: "Pro-apoptotic activity of a-bisabolol in preclinical models of primary human acute leukemia cells"
13    39    0
Bioluminescence - Recent Advances in Oceanic Measurements and Laboratory Applications

Bioluminescence - Recent Advances in Oceanic Measurements and Laboratory Applications
200    54    0
báo cáo hóa học:

báo cáo hóa học:" Pro-apoptotic activity of a-bisabolol in preclinical models of primary human acute leukemia cells"
13    35    0
Báo cáo khoa học:

Báo cáo khoa học: "Beneficial effects of erythropoietin in preclinical models of shock and organ failure"
2    74    0
Standard Practice in Sexual Medicine

Standard Practice in Sexual Medicine
416    73    0
The New Car Assessment Program Suggested Approaches for Future Program Enhancements

The New Car Assessment Program Suggested Approaches for Future Program Enhancements

26    49    0
Assessing the translatability of In vivo cardiotoxicity mechanisms to In vitro models using causal reasoning

Assessing the translatability of In vivo cardiotoxicity mechanisms to In vitro models using causal reasoning
12    71    0
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: Causal modeling, timing, and classes of concomitant medications

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: Causal modeling, timing, and classes of concomitant medications
13    92    0
Clinical association of progesterone receptor isoform A with breast cancer metastasis consistent with its unique mechanistic role in preclinical models

Clinical association of progesterone receptor isoform A with breast cancer metastasis consistent with its unique mechanistic role in preclinical models
10    53    0
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
8    103    0
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
12    41    1
Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters

Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters
15    80    1
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
10    59    1
Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma

Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma
10    50    1
A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities
12    44    1